ABC | Volume 114, Nº4, Abril 2020

Artigo Original Albuquerque et al. Polimorfismo Ser49Gly na insuficiência cardíaca Arq Bras Cardiol. 2020; 114(4):616-624 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 23. Leineweber K, Frey UH, Tenderich G, Toliat MR, Zittermann A, Nürnberg P, et al. The Arg16Gly- β (2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(4):357-65. 24. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, Luca V, et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patientswithidiopathicdilatedcardiomyopathy.AmJMed.2004;117(7):451-8. 25. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44-8. 26. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail. 2009;15(3):191-8. 624